Biological monitoring of cancer patients: problems encountered in tumour marker assays;Surveillance biologique en cancérologie : problèmes rencontrés avec les dosages de marqueurs tumoraux

Immuno-Analyse et Biologie Specialisee

Volumn 22, Issue 1, 2007, Pages 34-40

  Pichon, M F ^a   Eche, N ^b   Basuyau, J P ^c   Riedinger, J M ^d  

^a CENTRE RENÉ HUGUENIN   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Biological monitoring; Results interpretation; Standardisation; Tumour markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ARTICLE; BIOLOGICAL MONITORING; CANCER PATIENT; CANCER STAGING; DIAGNOSTIC VALUE; HUMAN; PRIORITY JOURNAL; STANDARDIZATION; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

EID: 33847707912     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2006.11.004     Document Type: Article

References (11)

1. ANAES (Agence Nationale d'Accréditation et d'Evaluation en Santé). Marqueurs sériques dans les cancers du sein et les cancers colorectaux. Gastroenterol. Clin. Biol. 22 (1998) 442-447
2. Basuyau J.P., Leroy M., and Brunelle P. Determination of tumor markers in serum. Pitfalls and good practice. Clin. Chem. Lab. Med. 39 (2001) 1227-1233
3. Bioforma, Riedinger JM, Eche N, Basuyau JP, Pichon MF. Les marqueurs tumoraux des tumeurs solides. Cahier de formation n° 32. Bioforma 2005. www.bioforma.net.
4. Contrôle international de qualité Oncocheck. Cis Bio International, Gif sur Yvette, France.
5. Corone C., Collignon M.A., Alberini J.L., Pichon M.F., and Pecking A.P. Place de la TEP FDG dans la prise en charge des cancers mammaires et gynécologiques. Med. Nucl. 25 (2001) 331-339
6. De la Lande B., Hacene K., Floiras J.L., Alatrakchi N., and Pichon M.F. Prognostic value of CA 15-3 kinectics for metastastic breast cancer. Int. J. Biol. Markers 17 (2002) 231-238
7. Duffy M.J. Serum tumor markers in breast cancer: are they of clinical value?. Clin. Chem. 52 (2006) 345-351
8. Pichon M.F. Rôle des marqueurs tumoraux dans le comportement biologique de tumeurs solides. Imm. Biol. Spec. 19 (2004) 241-249
9. Riedinger J.M., Wafflart J., Ricolleau G., Eche N., Larbre H., Basuyau J.P., et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome. Results of a French multicentric study. Ann. Oncol. 17 (2006) 1234-1238
10. Soletormos G., Schioler V., Nielsen D., Skovsgaard T., and Dombernowski P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin. Chem. 39 (1993) 2077-2083
11. WGTM (Working Group on Tumour Marker). ISOBM (International Society of Biological Markers). Tumor Biol. 11 (1990) 287-288